On June 26, 2025, Kymera Therapeutics, Inc. announced a follow-on offering of 5,044,500 shares at $44.00 each, aiming to raise approximately $237.3 million to support its clinical programs, with a closing date of June 30, 2025. The offering includes an option for underwriters to purchase an additional 855,000 shares.